AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis
UC Is Final Planned Indication For IL-23 Inhibitor
Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.
